Cotización Ocugen - OCGN

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

0.7701

Postura de Compra

0.765

Postura de Venta

0.775

Volume Operado de la Acción

21,582,681

0.73 Rango del Día 0.7999

0.37 Rango de 52 semanas 2.105

Capitalización de Mercado [m]

224.346M

Precio Anterior

0.7679

Precio de Apertura

0.751

Hora

266

0.7701

(formt)

Última hora de negociación

Volumen financiero

US$ 16,564,751

Precio Promedio Ponderado

0.767502

Volumen promedio (3 m)

3,731,253

Acciones en circulación

291,320,280

Rendimiento del Dividendo

Ratio Precio/Utilidad

-3.56

Beneficio por acción (BPA)

-0.22

turnover

6.04M

Beneficio neto

-63.08M

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal... Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. Mostrar más

Sector

Biological Pds,ex Diagnstics

Industria

Ortho,prosth,surg Appl,suply

Sitio web

ocugen.com

Sede

Wilmington, Delaware, USA

Fundado

2020

Ocugen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker OCGN. The last closing price for Ocugen was US$0.77. Over the last year, Ocugen shares have traded in a share price range of US$ 0.37 to US$ 2.105.

Ocugen currently has 291,320,280 shares in issue. The market capitalisation of Ocugen is US$223.70 million. Ocugen has a price to earnings ratio (PE ratio) of -3.56.

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular...

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Form 4 - Statement of changes in beneficial ownership of securities

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.0899	-10.4534883721	0.86	0.89	0.7417	5993661	0.80017858	CS
4	-0.1429	-15.6516976999	0.913	1.02	0.7417	4120927	0.8653842	CS
12	-0.2203	-22.2435379645	0.9904	1.13	0.7417	3731253	0.92764169	CS
26	-0.5999	-43.7883211679	1.37	1.979	0.7417	4316795	1.19536368	CS
52	0.3766	95.7052096569	0.3935	2.105	0.37	5802500	1.25993505	CS
156	-5.0099	-86.6764705882	5.78	5.78	0.345	6136393	1.82468854	CS
260	0.3901	102.657894737	0.38	18.77	0.17	16631010	5.36387527	CS

OCGN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Ocugen?

El precio actual de las acciones de Ocugen es US$ 0.7701

¿Cuántas acciones de Ocugen están en circulación?

Ocugen tiene 291,320,280 acciones en circulación

¿Cuál es la capitalización de mercado de Ocugen?

La capitalización de mercado de Ocugen es USD 223.7M

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Ocugen?

Ocugen ha negociado en un rango de US$ 0.37 a US$ 2.105 durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Ocugen?

El ratio precio/beneficio de Ocugen es -3.56

¿Cuál es el ratio de efectivo a ventas de Ocugen?

El ratio de efectivo a ventas de Ocugen es 37.2

¿Cuál es la moneda de reporte de Ocugen?

Ocugen presenta sus resultados financieros en USD

¿Cuál es el último ingresos anual de Ocugen?

El último ingresos anual de Ocugen es USD 6.04M

¿Cuál es el último beneficio anual de Ocugen?

El último beneficio anual de Ocugen es USD -63.08M

¿Cuál es la dirección registrada de Ocugen?

La dirección registrada de Ocugen es CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

¿Cuál es la dirección del sitio web de Ocugen?

La dirección del sitio web de Ocugen es ocugen.com

¿En qué sector industrial opera Ocugen?

Ocugen opera en el sector ORTHO,PROSTH,SURG APPL,SUPLY

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M